entertainment -WSS

entertainment

author：leisure time 2025-08-19 15:01:39 - browse：845

The Food and Drug Administration’s advisory panel of pediatric experts met on Tuesday to discuss advances in artificial womb technology, which aim to save the lives of premature babies.

The goal of the meeting was to discuss measures for evaluating the safety and efficacy of an artificial womb. The group grappled with the limits of current animal data, as well as the ethical difficulties in running human trials. On Wednesday, the committee’s meeting will be closed to the public in order to protect trade secrets.

Extremely premature babies, defined as infants born at less than 28 weeks, rarely survive. About half of infants born at 23 weeks survive, according to a 2022 study in the Journal of the American Medical Association, and at 22 weeks just 10% survive. This population represents less than 2% of all premature babies, but the problem is growing; the Centers for Disease Control and Prevention reported that the preterm birth rate rose by 4% between 2020 and 2021.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： NVIDIA and Google execs on the future of AI and drug discovery

WSS

FDA clears Verve to begin U.S. study of gene

When prostate cancer spreads, where it goes matters

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Readout LOUD podcast: Live from STAT Breakthrough Summit West

With measles on the rise, a personal story of a devastating disease

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

leisure time

entertainment

entertainment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Venture capitalist Bob Kocher on the state of digital health

Affirmative action in medical school literally saved lives

CZI to create biohub to build anti

Drug repurposing or repositioning? The language matters

Glen Campbell's doctor discusses his public struggle with Alzheimer's

How one medical school became remarkably diverse

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Medicare details structure of new drug price negotiation program

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

focus

CZI to create biohub to build anti

Cytokinetics CEO stresses company can launch heart drug on its own

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Addiction experts warn against a second 'war on drugs'

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

explore

hotspot

focus

entertainment